Taisho Banks On Ageing To Spur Japanese Growth
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Taisho Pharmaceutical is hoping Japan’s ageing population will act as a catalyst for growth at its domestic Self-Medication business in the coming years, according to the group’s chief executive officer Akira Uehara.
You may also be interested in...
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
Euro Q1 Consumer Health Earnings Preview: Reckitt, Sanofi, Haleon, Bayer
Major Europe-based consumer health players Reckitt, Sanofi, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2024 results over the coming weeks.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.